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The emergence of metallo--lactamase (MBL)-producing isolates is a challenge to routine microbiology
laboratories, since there are no standardized methods for detecting such isolates. The aim of this study was to
evaluate the accuracy of different phenotypic methods to detect MBL production among Pseudomonas spp.,
Acinetobacter spp., and enterobacterial isolates, including GIM, IMP, SIM, SPM, and VIM variants. A total of
46 genetically unrelated Pseudomonas aeruginosa, Pseudomonas putida, Acinetobacter sp., and enterobacterial
strains producing distinct MBLs were tested. Nineteen strains were included as negative controls. The
inhibition of bacterial growth and -lactam hydrolysis caused by MBL inhibitors (IMBL) also were evaluated.
The isolates were tested for MBL production by both a double-disk synergy test (DDST) and a combined disk
assay (CD) using imipenem and ceftazidime as substrates in combination with distinct IMBL. One hundred
percent sensitivity and specificity were achieved by DDST using 2-mercaptopropionic acid in combination with
ceftazidime and imipenem for the detection of MBL production among P. aeruginosa and Acinetobacter species
isolates, respectively. The CD test showed the same results for detecting MBL-producing enterobacteria by
combining imipenem and EDTA, with a 5.0-mm-breakpoint increase in the size of the inhibition zone. Our
results indicate that both phenotypic methods to detect MBL-producing isolates should be based on the genera
to be tested, regardless of the enzyme produced by such isolates, as well as on the local prevalence of MBL
producers.
Since the early 1990s, new metallo--lactamase (MBL)-en-
coding genes have been reported all over the world in clinically
important pathogens, such as Pseudomonas spp., Acinetobacter
spp., and members of the Enterobacteriaceae family (19, 27, 35,
40). The emergence of MBL-encoding genes is worrisome,
since they usually are carried by mobile genetic structures with
great ability to spread (3, 5, 18, 24, 36). Moreover, increased
mortality rates have been documented for patients infected
with MBL-producing Pseudomonas aeruginosa, especially due
to inadequate empirical therapy (39). Therefore, early detec-
tion of MBL-producing organisms is crucial to establish appro-
priate antimicrobial therapy and to prevent their inter- and
intrahospital dissemination (10, 35).
Several phenotypic methods based on MBL inhibition by
EDTA or thiol-based compounds have been published. Al-
though they are simple to perform and cheaper than genotypic
methods, they have shown discordant results depending on the
employed methodology, -lactam substrates, MBL inhibitors
(IMBL), and bacterial genus tested (11, 14, 17, 21, 26). In
addition, SPM-, GIM-, and SIM-producing pathogens rarely
have been evaluated by these studies.
The high diversity and prevalence of MBL-producing P.
aeruginosa, Acinetobacter spp., and Enterobacteriaceae isolates
have motivated the search for an accurate MBL screening test.
The aim of this study was to evaluate the accuracy of the
double-disk synergy test (DDST) and the combined disk (CD)
assay to screen for MBL-producing isolates among P. aerugi-
nosa, Acinetobacter spp., and selected Enterobacteriaceae iso-
lates that are producers of either IMP, GIM, SIM, SPM, or
VIM enzymes.
MATERIALS AND METHODS
Bacterial isolates. All strains tested in this study are described in Table 1.
MBL-positive controls. A total of 46 MBL-producing isolates, including Acine-
tobacter spp. (n  10), P. aeruginosa (n  28), Pseudomonas putida (n  1), and
enterobacterial isolates (n  7), were selected as positive controls. All 46 isolates
previously had their genotypes characterized by PCR and sequencing. When
applicable, these isolates were molecularly typed again to ensure that they were
genetically unrelated. Additionally, all isolates showed resistance or reduced
susceptibility to imipenem and resistance to ceftazidime according to CLSI
breakpoints (9).
MBL-negative controls. Nineteen non-MBL producers, previously screened
for the presence of MBL genes (blaIMP, blaGIM, blaSIM, blaSPM, and blaVIM),
were included as negative controls (23). In addition, to exclude the possible
presence of other not-yet-described MBL enzymes, the imipenemase activity of
cell sonicates from overnight broth cultures were determined by spectrophoto-
metric assays using a BioMate 5 UV-visible spectrophotometer. This experiment
was carried out with 150 M imipenem as the substrate at 299 nm. All selected
negative control isolates also showed reduced susceptibility to ceftazidime and/or
imipenem and were genetically unrelated by random amplification of polymor-
phic DNA (data not shown).
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IMBL growth inhibition activity. The bacterial growth inhibition initially was
evaluated by disk diffusion testing 5 l of different concentrations of each MBL
inhibitor (IMBL) against Pseudomonas aeruginosa ATCC 27853. The IMBLs
used were EDTA (Sigma, Steinheim Germany), mercaptopropionic acid (MPA;
Sigma); mercaptoacetic acid (MAC; Sigma); mercaptoethanol (MET; Gibco,
New York, NY); and phenanthroline (PHEN; Sigma). The tested IMBL con-
centrations were the following: (i) EDTA, 50, 100, 300, and 500 mM; (ii) MPA,
11.2 (undiluted), 5.6 (1:2), 2.8 (1:4), and 1.4 mM; (iii) MET, 55 (undiluted), 27.5
(1:2), 13.2 (1:4), and 7.0 mM (1:8); (iv) MAC, 14.4 (undiluted), 7.2 (1:2), 3.6
(1:4), 1.2 (1:12); and (v) PHEN, 8, 4, 2, and 1 mM.
Five microliters of the IMBL solution presenting the smallest inhibition zone
in the absence of -lactam agents was selected to perform the DDST. Different
amounts of the same solution were employed to perform the CD test, ranging
from 2 to 10 l of each IMBL.
The evaluation of the interference of IMBL itself on the growth of each one
of the isolates used in this study also was performed by dropping the same
volumes of each IMBL employed for the CD assay on a blank disk. The inhibi-
tion zones were measured after overnight incubation at 35°C, and the means of
inhibition zones were calculated.
Hydrolysis tests. To assess the -lactam hydrolysis by each IMBL, the hydro-
lysis rates of -lactams were measured with a BioMate 5 UV-visible spectropho-
tometer. The antimicrobial powder was diluted to obtain 1.8 to 2.0 U of absor-
bance. Briefly, 100 l of each selected IMBL solution was added to 900 l of
antimicrobial solution. Experiments were carried out at 299 and 260 nm for
imipenem and ceftazidime, respectively.
Phenotypic detection of MBL. (i) DDST. The phenotypic tests were performed
by following the CLSI recommendations for the disk diffusion method (9).
Briefly, a 0.5 McFarland bacterial suspension was inoculated on a Mueller-
Hinton (MH) agar plate (Oxoid, Basingstoke, England). Imipenem and ceftazi-
dime disks were aligned around blank filter disks, which contained 5 l of the
chosen inhibitor solution added directly on the disk and already placed on the
MH agar plate. The following distances between the inhibitor and the substrates
were tested: 1.0, 1.5, 2.0, 2.5, and 3.0 cm (from center to center). The appearance
of either an enhanced or a phantom zone between the antimicrobial agents and
the inhibitor disk was considered a positive result and indicative of MBL pro-
duction. The best substrate, IMBL, and distance between the antimicrobial agent
and the IMBL disks to detect MBL producers were selected according to the
highest sensitivity (SN) and specificity (SP) results.
(ii) CD assay. For the CD assay, ceftazidime and imipenem disks initially were
placed on the inoculated MH plates with a 0.5 McFarland bacterial suspension,
and 2, 4, 6, 8, or 10 l of each inhibitor solution was added directly to the disks
(1). The amounts of each IMBL solution added to the disks corresponding to 2-,
4-, 6-, 8-, and 10-l volumes, respectively, were the following: (i) EDTA, 74, 148,
222, 297, and 370 g; (ii) MPA, 0.295, 0.592, 0.888, 1.184, and 1.48 g; (iii) MET,
8.58, 17.16, 25.74, 34.32, and 42.92 g; (iv) MAC, 0.221, 0.441, 0.662, 0.883, and
1.104 g; and (v) PHEN, 3.17, 6.34, 9.51, 12.68, and 15.85 g. After an 18- to
24-h incubation period at 35°C, the increase in the size of the inhibition zone
obtained with the CD compared to that of the antimicrobial disk alone was
measured. The positive criteria for classifying an isolate as an MBL producer is
described below.
Statistical analysis. The inhibition zone (in millimeters) produced by each
IMBL alone was measured for each tested concentration, and the differences
among means (positive and negative controls) were assessed by the Student’s t
test.
SN, SP, and positive and negative predictive values (PPV and NPV, respec-
tively) were calculated for the DDST for each -lactam/IMBL combination for
the five distances evaluated: 1.0, 1.5, 2.0, 2.5, and 3.0 cm. PCR results for each
MBL were considered the gold standard, and isolates were considered true MBL
producers if they were positive for blaIMP, blaGIM, blaSIM, blaSPM, or blaVIM.
SN, SP, PPV, and NPV were calculated with the formulas a/(a  c), d/(b  d),
a/(a  b), and d/(c  d), respectively, where a represents the number of isolates
correctly identified as MBL producers by the DDST, c is the number of true
TABLE 1. MBL-producing isolates and non-MBL-producing isolates used in this study as positive and negative controls, respectively
Isolate group Species (no. tested) MBL type Country of origin Strain no(s). Referenceor source
MBL producing Acinetobacter spp. (7) IMP-1 Brazil A3035, A4861, A3880, A68,
A4764, A4468, A129046
30
Acinetobacter spp. (2) IMP-1 Brazil A695, A696 This study
Acinetobacter spp. (1) SIM-1 Korea YMC 03/9/T104 18
P. aeruginosa (9) IMP-1 Brazil 131, 144, 137, 98, 128, 130,
143, 145, 183
29
P. aeruginosa (1) IMP-1 Japan PSA 320 13
P. aeruginosa (1) IMP-13 Italy 86-10079 31
P. aeruginosa (1) IMP-16 Brazil 101-4704 24
P. aeruginosa (1) IMP-18 Brazil 3486 36
P. aeruginosa (1) IMP-18 Brazil 3489 This study
P. aeruginosa (1) GIM-1 German 73-5671 7
P. aeruginosa (1) VIM-1 Italy 179 This study
P. aeruginosa (1) VIM-2 Brazil 225 This study
P. aeruginosa (1) VIM-7 United States 07-406 32
P. aeruginosa (1) SPM-1 Brazil 48-1997 A 33
P. aeruginosa (9) SPM-1 Brazil 14, 44, 73, 75, 76, 83, 194,
196, 197
6
P. putida (1) IMP-1 Brazil 48-12346A 22
K. pneumoniae (2) IMP-1 Brazil KPN1, KPN2 5
Enterobacter cloacae (1) VIM-1 Italy 75-10344 3
Enterobacter cloacae (2) VIM-1 Italy ECL3, ECL4 5
Enterobacter cloacae (1) IMP-1 Brazil 199 4
Serratia marcescens (1) IMP-1 Japan SM 319 13
Non-MBL producing Acinetobacter spp. (1) OXA-23 Brazil 216 This study
Acinetobacter spp. (5) NAa Brazil 210, 211, 212, 213, 215 This study
P. aeruginosa (6) NA Brazil 209, 227, 230, 224, 237, 238 This study
K. pneumoniae (3) NA Brazil 189, 222, 223 This study
Enterobacter cloacae (1) NA Brazil 221 This study
Morganella morganii (1) NA Brazil 224 This study
Serratia marcescens (1) NA Brazil 190 This study
Serratia marcescens (1) SME United States 1065 12
a NA, not applicable.
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MBL producers (positive controls) that were incorrectly assigned as non-MBL
producers by DDST, d is the number of true isolates that are non-MBL produc-
ers (negative controls) that were correctly identified by DDST, and b is the
number of isolates that were incorrectly identified as MBL producers.
Results from the CD phenotypic method were characterized by receiver op-
erating characteristic (ROC) curves to choose the best cutoff values for indicat-
ing MBL production. For each IMBL, the SN and SP of all five concentrations
were calculated successively according to the variation of inhibition zones of
MBL-producing and non-MBL-producing isolates. The resulting SN values then
were plotted against the corresponding values of 1  SP, producing an ROC
curve. The area under the ROC curve (AUC) and its standard error were
calculated, and its statistical significance then was evaluated by the nonparamet-
ric method. Differences between variables’ AUCs were evaluated through a
comparison of the 95% confidence intervals of the corresponding areas.
CD and DDST analyses also were stratified into seven groups according to
pathogen species and MBL type produced, as follows: (i) general group, includ-
ing all isolates tested; (ii) Acinetobacter spp. group; (iii) P. aeruginosa group; (iv)
enterobacterial group; (v) IMP-producing isolate group; (vi) VIM-producing
isolate group; and (vii) SPM-producing isolate group. For the analysis of the
MBL type groups (IMP, VIM, and SPM), all 19 negative controls were included.
On the other hand, only negative controls representative of the same genus/
species or bacterial family were selected for the pathogen (groups ii to iv)
analysis. For example, the analysis of P. aeruginosa included all 28 MBL-produc-
ing P. aeruginosa isolates and the 6 non-MBL-producing P. aeruginosa isolates.
The statistical analysis was performed using SPSS 10.0 for Windows and Epi
Info (CDC), version 6.04. All reported P values were two sided, and values below
0.05 were considered statistically significant.
RESULTS
IMBL growth inhibition activity. PHEN and MET showed
no growth inhibition activity on P. aeruginosa ATCC 27583 at
all tested concentrations. On the other hand, EDTA, MPA,
and MAC inhibited the bacterial growth of P. aeruginosa
ATCC 27583 differently. The IMBL concentrations of 100 mM
EDTA, 1.4 mM MPA, 55 mM MET, 1.2 mM MAC, and 8 mM
PHEN were chosen to be tested against the 65 genetically
unrelated isolates, since they showed the lowest level of inhi-
bition of bacterial growth (Table 2). Overall, EDTA, PHEN,
and MET presented weak bactericidal activity, with an increase
in the size of inhibition zones of 0 to 2 mm. In contrast, MPA
produced a larger increase in the size of the inhibition zones,
from 0.3 to 12.4 mm (Table 2). Despite increasing the IMBL
volumes applied to the blank disks, the mean sizes of the
inhibition zones were similar among MBL-producing and non-
MBL-producing strains (P 0.05), except for MAC at 10 l (P
0.05). Therefore, the bactericidal effect of IMBL was not in-
fluenced by the production of IMP, VIM, SPM, GIM, or SIM,
making no difference to the calculation of SN and SP values.
Hydrolysis tests. Hydrolysis test results showed that EDTA
and PHEN were not able to hydrolyze the antimicrobial agents
tested, while MAC, MET, and MPA demonstrated hydrolytic
activity against imipenem but not against ceftazidime (data not
shown). The hydrolysis of imipenem, ceftazidime, ampicillin,
and aztreonam by MPA has been observed already (14); how-
ever, the ability of other IMBLs to hydrolyze -lactam agents
has not been seen previously.
Phenotypic MBL detection by DDST. Table 3 shows the
results of SN, SP, PPV, and NPV for DDST. According to the
statistical analysis, PHEN and MET demonstrated a very poor
ability to detect the tested MBL-producing strains, providing
SN results for less than 20% of all 46 MBL-producing isolates
(data not shown). Surprisingly, four isolates (GIM, IMP-18
[isolate 3489], a VIM-1-producing P. aeruginosa, and an SIM-
1-producing Acinetobacter sp.) were categorized as MBL pro-
ducers by MET, even when the distance between MET and the
-lactam disks was 3.0 cm. Further studies that included an
increasing number of SIM- and GIM-producing isolates would
be important to confirm the MET capability for MBL pheno-
typic detection.
When all 46 MBL-producing isolates (the general group)
were analyzed, MPA provided the best results by using imi-
penem as the substrate. The SN, SP, PPV, and NPV at 1.5 cm
were 93.5, 89.5, 95.6, and 85.0%, respectively. However, better
SN and SP were achieved after stratifying the results into
groups. The Acinetobacter sp. group had SP, SN, PPV, and
NPV of 100% when imipenem was placed at 1.5 or 2.0 cm from
the MPA disks. For the P. aeruginosa group, DDST results
identical to those for the Acinetobacter sp. group were obtained
using ceftazidime as a substrate and MPA as the IMBL at 2.0
or 2.5 cm. Figure 1 illustrates the DDST results for MBL-
producing P. aeruginosa and Acinetobacter spp. isolates, using
EDTA and MPA in combination with both imipenem and
ceftazidime at a 2.0-cm distance between disks. Among the
enterobacterial isolates, identical SN (100.0%), SP (85.7%),
PPV (85.7%), and NPV (100.0%) were detected with either
EDTA/imipenem or MAC/imipenem at 1.5 and 2.0 cm, respec-
tively, by DDST (Table 3). SP results did not reach 100% due
to the occurrence of false-positive DDST results, as illustrated
in Fig. 1.
Distinct results for EDTA and MPA were observed for the
IMP and VIM groups (Table 3). For the IMP group, SN and
SP results close to 90% were achieved only for MPA/imipenem
at 1.5 cm. For VIM, 100% SN was achieved only by using
TABLE 2. Inhibition of bacterial growth due to MBL inhibitors
IMBL
(vol, in l)
Mean inhibition zone size (in mm) by
strain type
P value
MBL producer
(n  46)
Non-MBL producer
(n  19)
EDTA (2) 6.0a 6.0 –b
EDTA (4) 6.1 6.0 –
EDTA (6) 6.4 6.0 –
EDTA (8) 6.7 6.0 –
EDTA (10) 7 6.0 –
MPA (2) 7.3 6.3 0.1
MPA (4) 10.8 10.9 0.9
MPA (6) 13.5 14.4 0.78
MPA (8) 16.1 16.7 0.3
MPA (10) 18.4 18.2 0.8
MAC (2) 6.1 6.0 –
MAC (4) 7.6 7.5 0.76
MAC (6) 10.6 9.6 0.12
MAC (8) 12.6 11.7 0.24
MAC (10) 14.9 13.1 0.05
MET (2) 6.0 6.2 –
MET (4) 6.8 6.3 0.35
MET (6) 7.5 7.2 0.8
MET (8) 8.0 7.2 0.6
MET (10) 8.0 7.4 0.65
PHEN (2) 6.0 6.0 –
PHEN (4) 6.2 6.0 –
PHEN (6) 6.5 6.3 0.8
PHEN (8) 6.9 6.4 0.3
PHEN (10) 7.6 7.3 0.78
a No inhibition zone was detected, since the size of the paper disk was 6 mm.
b –, The P value could not be calculated due to a lack of variation in the means
of inhibition zones.
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EDTA/imipenem at 1.5 cm. SPM group results were similar to
those for the P. aeruginosa group, for which MPA/ceftazidime
provided 100% SN and nearly 90% SP by using a 2.5-cm
distance. The same values also were achieved for detecting
SPM using the MPA/imipenem combination at 1.5 cm (Table
3). Since many SPM, VIM, and IMP isolates are P. aeruginosa,
we also performed a second analysis, including only P. aerugi-
nosa as the positive and negative controls for each MBL sub-
group. For SPM-, VIM-, and IMP-producing P. aeruginosa
isolates, 100% SN and SP were obtained for 2.0- and 2.5-cm
distances by using MPA/ceftazidime (data not shown).
We also selected all IMP-producing Acinetobacter spp. to
perform a stratified analysis. Compared to the results for non-
MBL-producing Acinetobacter spp., SN and SP results reached
100% using MPA/imipenem at 1.5 and 2.0 cm (data not
shown). These results were identical to those for the Acine-
tobacter sp. group (Table 3).
Phenotypic MBL detection by CD test. All of the CD test
results were applied in the construction of ROC curves to
establish the best breakpoint (increase in millimeters) for MBL
detection. Table 4 shows selected CD results. Since the study’s
priority was to select a screening test that yielded the lowest
number of false-negative results, only SN results greater than
80% were included in Table 4. In analyzing the general group,
the CD test resulted in SN values greater than 80% for EDTA/
imipenem and EDTA/MPA/ceftazidime. However, SP results
varied greatly, from 31.6 to 89.5%.
The Acinetobacter sp. group was not accurately classified by
the CD test (Fig. 2 and Table 4). The best SN and SP results
were 80.0 and 100.0%, respectively, for 2 l of MPA associated
with imipenem, using a breakpoint of 0.5 mm (AUC  0.9).
However, the increase of 0.5 mm is considered a nondiscrim-
inatory cutoff, since it cannot be adequately measured by visual
inspection. All other AUCs displayed results from 0.24 to 0.54.
The P. aeruginosa group showed SN results close to 100%
and SP results of 100% (Table 4) for ceftazidime in combina-
tion with EDTA or MPA, using 8 mm as breakpoint. Figure 3
shows the ROC graphs for ceftazidime in combination with
EDTA and MPA. The best AUC (0.98) was achieved by testing
8 l of MPA. All AUC results for EDTA and MPA were
statistically significant (P  0.05) (data not shown).
Surprisingly, the CD results for the enterobacterial group
achieved 100% SN and 100% SP for several of the breakpoints
analyzed by the ROC curve for the imipenem/EDTA combi-
nation (AUC  1.0) (Table 4). Figure 1 shows an example of
a negative CD assay for a non-MBL producer, Klebsiella pneu-
moniae, which was misclassified as an MBL producer by
DDST.
Among the MBL groups, the combination of ceftazidime
associated with EDTA (6 and 8 l) or MPA (2 to 8 l) resulted
FIG. 1. Phenotypic tests to detect MBL production. (A and B) DDST results using EDTA and MPA as the IMBL for P. aeruginosa and
Acinetobacter spp. at a distance of 2.0 cm (center to center) between disks. (A) Imipenem presented the best results for screening for Acinetobacter
spp. (B) Ceftazidime increased the test SN for screening for MBL production among P. aeruginosa strains. (C and D) DDST and CD assays
performed with a non-MBL-producing K. pneumoniae strain. (C) The DDST yielded an inhibition zone with distortion toward the EDTA disk.
(D) The CD assay yielded a negative result.
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in 100% SN and 100% SP for detecting the SPM-producing
isolates (Table 4).
DISCUSSION
The detection of MBL-producing isolates by PCR is expen-
sive, requires specialized technicians and instruments, and,
more importantly, is able to detect only previously described
MBL-encoding genes. In addition, the cost of implementing
this technique might not be justified in medical centers that
have a low prevalence of MBL producers. These factors make
the implementation of such tests by routine clinical microbiol-
ogy laboratories difficult. However, the detection of the MBL
phenotype of resistance is of crucial importance for selecting
the most appropriate therapy and applying infection control
measures. For these reasons, an accurate and easy-to-perform
phenotypic test is desirable and urgently necessary in hospitals
with a high prevalence of MBL-producing isolates (10, 35).
Many authors have published distinct phenotypic techniques
for screening MBL-producing isolates; however, these studies
have important limitations, such as the following: (i) the inclu-
sion of a small number of MBL-producing isolates, sometimes
harboring the same type of enzyme (2, 36); (ii) the absence of
molecular typing to exclude the influence of a single clone in
the interpretation of their results (28); (iii) a lack of tests for
evaluating the inhibitory effect of IMBL activity on bacterial
growth and -lactam hydrolysis (2, 11, 26, 34, 37); (iv) no
inclusion of SPM- or GIM-producing P. aeruginosa isolates or
SIM-producing Acinetobacter spp. isolates (11, 14, 17, 21, 25);
(v) a lack of results stratified according to pathogen/species, in
which the SN and SP values reflect the overall performance of
all isolates (2, 14, 17); and (vi) accurate statistical analysis
usually is not carried out to interpret and validate their results
(2, 11, 21, 37, 38).
This is the first study to assess the accuracy of phenotypic
methods to detect all of the major types of mobile MBLs
described (GIM, IMP, SIM, SPM, and VIM) that are produced
by diverse bacterial genera with distinct imipenem susceptibil-
ity patterns. The inclusion of genetically unrelated strains iso-
lated on three distinct continents suggests that these results
would be useful for regions in which such a resistance mech-
anism is frequent. Depending on the tested concentration,
IMBLs may possess their own bactericidal activity, which may
result in expanded inhibition zones not associated with true
MBL production (8). This finding may lead to the false-posi-
tive detection of MBL by both CD assay and DDST, and it has
been considered a disadvantage to employ EDTA and MPA as
IMBL (16). To exclude the effect of such interference on the
phenotypic detection of MBL, we have tested the activity of
FIG. 2. ROC curve from different volumes of MPA in combination
with imipenem for Acinetobacter spp.
FIG. 3. ROC curve from different volumes of EDTA (A) and MPA (B) in combination with ceftazidime for P. aeruginosa.
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distinct dilutions of IMBL with respect to the growth of P.
aeruginosa ATCC 27853. In addition, the influence of IMBL
inhibitory activity on the substrate was taken into consider-
ation in the analysis of SN and SP results for screening MBL-
producing isolates. False-negative results might arise from the
imipenem hydrolysis caused by thiol derivatives (14). Many
studies have performed phenotypic MBL detection using
Pseudomonas spp., Acinetobacter spp., and/or enterobacterial
isolates, but some of them did not present SP and SN results
stratified by pathogen/species, reflecting the global perfor-
mance of all isolates and not for a specific pathogen (11).
Other studies did stratify according to species, but it is not
clear if only negative controls from the same pathogen/species
were included to calculate SN and SP results (21, 37). This is a
very important issue that must be taken into consideration
when selecting an MBL phenotypic test, as in this study we
have observed different SP and SN values according to the
group analyzed. Moreover, a rigorous statistical analysis of our
data was performed.
In this study, PHEN and MET showed poor results for
detecting MBL producers under the tested conditions. The
IMBL derivatives of thiol compounds may possess anionic,
cationic, or neutral functional groups at neutral pH. MAC and
MPA are classified in the anionic group, while MET belongs to
the neutral group. Siemann et al. have shown that the inhibi-
tion of MBL activity by the anionic IMBL starts immediately.
In contrast, neutral IMBLs have a pronounced lag prior to the
start of inhibitory activity; i.e., the best inhibitory results are
achieved after preincubating the IMBL with MBL before add-
ing the substrate. In this manner, the weakest activity of MET
in this study could be explained by the absence of the prein-
cubation step in the performance of the phenotypic detection
(28).
The standardization of a phenotypic method to screen MBL-
producing isolates is of crucial importance (10). Most previous
studies that evaluated MBL phenotypic detection were per-
formed under distinct experimental conditions, jeopardizing
the comparison of their results to those of others (2, 11, 14, 15,
21, 25, 26). The sizes of inhibition zones produced by -lactam/
IMBL combinations may vary according to the way that the
IMBL is incorporated into the -lactam disks (1). Since the
selection of an appropriate breakpoint for screening MBL-
producing isolates is directly influenced by the size of the
inhibition zone, the methodology used for preparing the CDs
should always be described in such phenotypic reports. In the
current study, we have added the IMBL solutions directly on
-lactam disks already placed on the agar plate (1), while some
authors previously prepare and freeze IMBL/-lactams disks;
thus, the results of our CD assay may be comparable to those
of other studies that use the same methodology.
In addition, a number of authors also have raised concerns
about the influence of the bactericidal effect of IMBL alone,
claiming that it could not be distinguished from the antimicro-
bial effect of -lactam/IMBL (2, 8, 14, 16). Fortunately, we
have addressed this issue, since we have documented that the
best SN and SP results for CD assays were achieved by estab-
lishing breakpoints that were greater than the mean sizes of the
inhibition zones produced by all of the IMBL themselves.
When choosing the best MPA volume, we should take into
consideration the inhibitory effect of MPA itself on the bacte-
rial growth. According to Table 2, the mean increase in the size
of the of the inhibition zone caused by MPA itself (excluding
the diameter of the blank disk [6 mm]) varied from 1.3 (2 l)
to 12.4 mm (10 l). We recommend the addition of 2 l of
MPA to the ceftazidime disk, since this volume produced a
significant increase in the size of the inhibition zone (13 mm)
while exerting the minimal amount of inhibitory effect of MPA
itself during the bacterial growth when testing SPM-producing
isolates.
A ROC curve consists of a graph containing the relationship
between the SN and SP of a test, which are calculated for all
possible cutoff values. Thus, in this case, each curve plots the
true-positive rate against the false-positive rate for each vol-
ume of the IMBL/-lactam combinations. Since the ROC
graph is a result of SN versus 1  SP, the most accurate test to
discriminate between MBL- and non-MBL-producing isolates
would pass through the upper left corner of the graph. On the
other hand, the closer the curve comes to the 45-degree diag-
onal, the less accurate is the test. Additionally, the AUC is a
measure of the test’s accuracy and is useful for comparing
different tests. For example, an area of 1 represents an ideal
test (SN and SP of 100%), while an area of 0.5 reflects poor SN
and SP results (20). The greatest advantage of using ROC
curves in this case was the possibility of visualizing a wide range
of breakpoints for each IMBL/-lactam combination by the
CD test. In studies of different IMBL, many authors do not
consider testing a wide range of breakpoints. SN and SP results
usually are calculated only for a narrow range of breakpoints
that are chosen randomly or according to previously published
results (38). Moreover, many studies have established the best
breakpoints only by observing inhibition zones produced by the
IMBL/-lactam (11, 38). Thus, SN and SP values of all possible
and different breakpoints may not be presented and are not
known by the readers. In our study, a wide range of results
were documented and chosen based on ROC curve results,
ranging from 3 (for Enterobacteriaceae/imipenem/EDTA) to 18
mm (for SPM/MPA/ceftazidime). If we had tested only the
breakpoint of 7 mm, for example, we would have obtained less
accurate results for enterobacterial isolates (SN of 71.4% in-
stead of 100%) and SPM-producing isolates (SP of 31.6%
instead of 100%). Since higher SP results can be obtained only
by jeopardizing SN values, researchers should always consider
their main objective when selecting a screening method to
detect MBLs. However, due to the possible clinical implica-
tions of false-negative MBL results, microbiology laboratories
should always favor the selection of more sensitive methods.
TABLE 5. Optimal conditions described in this study to perform
phenotypic detection of MBL production among P. aeruginosa,
Acinetobacter spp., and Enterobacteriaceae clinical isolates
Isolate group Test IMBL -Lactamsubstrate
Expl
conditiona
Acinetobacter spp. DDST 5 l MPA
(1.4 mM)
Imipenem Distance,
2.0 cm
P. aeruginosa DDST 5 l MPA
(1.4 mM)
Ceftazidime Distance,
2.0 cm
Enterobacteriaceae CD 10 l EDTA
(100 mM)
Imipenem Breakpoint,
5 mm
a Breakpoint is the increase in the size of inhibition zone.
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As summarized in Table 5, our results show that the DDST
was the most accurate phenotypic test to detect MBL produc-
tion in P. aeruginosa and Acinetobacter spp. when 1.4 mM MPA
was used as the IMBL and was positioned 2 cm from the
-lactam disk. However, the choice of the best substrate de-
pended upon the bacterial species tested: ceftazidime and imi-
penem for P. aeruginosa and Acinetobacter spp., respectively.
By the CD assay, no breakpoint achieved 100% SN and SP for
the nonfermenting gram-negative bacilli. In contrast, among
the enterobacterial isolates, the CD test showed identical re-
sults (100% SN, 100% SP, and an AUC of 1) for different
EDTA volumes combined with imipenem. Thus, we suggest
that 10 l of 100 mM EDTA applied to the imipenem disk is
a good option to discriminate MBL-producing isolates, since it
produced the largest increase in the size of the inhibition
zone (5 mm). Due to the paucity of MBL-producing Entero-
bacteriaceae, only seven positive controls were included, and
we believe that further studies that evaluate an increased
number of MBL isolates are needed to corroborate our
results.
Concluding remarks. By DDST, MPA proved to be an ex-
cellent IMBL choice for detecting MBL among both P. aerugi-
nosa and Acinetobacter spp. Although the best distance varied
depending on the bacterial species, a distance of 2.0 cm could
be standardized, since 100% SN and 100% SP were achieved
for both pathogens. Since bacterial identification is determined
before susceptibility testing by routine clinical laboratories and
the type of MBL is yet unknown, the same solution of MPA
could be applied on a blank disk at 2.0 cm from imipenem (for
Acinetobacter spp.) or ceftazidime (for P. aeruginosa). Among
enterobacterial isolates, the CD test with imipenem associated
with 10 l of 100 mM EDTA was the most accurate combination
for detecting MBL production with a breakpoint of 5.0 mm.
We believe that the interpretation of DDST results is more
subjective than those of the CD assay (37), because the DDST
depends upon the technician’s expertise to discriminate true
synergism from the intersection of inhibition zones. However,
the CD assay did not show a good performance for screening
MBL-producing Acinetobacter spp.
The DDST is simple to perform and can be incorporated
into the existing workflow of clinical microbiology laboratories
that routinely employ disk diffusion as their preferential anti-
microbial susceptibility testing method. An MPA disk could be
easily placed at 2 cm from the imipenem or ceftazidime disk
during the performance of antimicrobial susceptibility testing
after the identification of Acinetobacter spp. and Pseudomonas
aeruginosa isolates. In our opinion, the detection of MBL-
producing isolates is of crucial importance not only for insti-
tutions with a high prevalence of such isolates but also in those
in which the phenotype of resistance has never been detected.
In a scenario of a high frequency of MBL-producing isolates,
the detection of such strains would be important for the ad-
justment of empirical antimicrobial therapy and, probably, the
reduction of mortality rates for patients infected with MBL-
producing isolates. The early detection of MBL-producing iso-
lates in institutions in which these strains have never been
detected would be important to avoid the intrahospital dissem-
ination of such strains, since most of the MBL-encoding genes
reside on class 1 integrons and/or plasmids that usually confer
high mobility to these genetic elements. However, clinical mi-
crobiology laboratories that usually perform susceptibility test-
ing by using automated systems would have an increase in their
work burden if an additional test was implemented for the
detection of this phenotype of resistance. In this manner, the
screening of MBL-producing isolates should be an individual
decision best made by each clinical laboratory in consultation
with the infectious disease practitioners and infection control
committees.
It is desirable that the selection of the appropriate MBL
tests to be performed is based upon studies providing SN and
SP results for that specific pathogen. Thus, we suggest that the
selection of the best MBL screening method should be based
on the isolated species, the local prevalence of MBL produc-
ers, and the ability of specialized technicians to correctly in-
terpret MBL inhibition.
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